Trial Profile
Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- 03 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 23 Mar 2022 Planned End Date changed from 30 Jul 2021 to 31 Dec 2022.
- 23 Mar 2022 Planned primary completion date changed from 30 Jul 2020 to 31 Dec 2022.